NCT03283787已完成不适用
A Single Site Randomized, Clinical Trial Comparing the Concomitant Use of MicroMatrix® With Cytal™ Wound Matrix 2-Layer to Standard of Care in Patients With Stage 3 or 4 Pressure Injuries
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Incidence of Complete Epithelialization
研究概览
简要总结
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 & 4 pressure ulcers using ACell products.
详细描述
A three arm, parallel-design, randomized study comparing 2 experimental arms to a single control arm. The primary comparison will be Group 1 (MicroMatrix® and ACell Cytal™ Wound Matrix 2-Layer vs. Group 3 (NPWT) to determine if Group 1 is superior to Group 3. NPWT is the standard of care (SOC) for patients with Stage 3 or 4 pressure ulcers and is the active control arm for the study.
A secondary comparison will be conducted comparing Group 2 (MicroMatrix® and ACell Cytal™ Wound Matrix 2-Layer plus NPWT) vs. Group 3 (NPWT) to determine if Group 2 is superior to Group 3.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form by subject or legally authorized representative.
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Male or female patients that are ≥ 21 years of age.
- •Body Mass Index (BMI) <
- •At least one Stage 3 or 4 pressure injury (NPUAP Staging Guidelines) present at the Screening and/or Treatment Visit located in any of the following regions:
- •Upper Extremity
- •i. Arm ii. Elbow iii. Wrist iv. Hand e. Sacral f. Hip g. Gluteal h. Ischial i. Lower Extremity i. Leg ii. Knee iii. Ankle iv. Heel v. Foot
- •Surface dimensions of pressure injury must be between 9 to 64 cm2 inclusive (as measured prior to treatment using a cm-scale ruler). The longest dimension must not exceed 10 cm; depth must not exceed 5 cm.
- •Wound must be >5 cm from the anus if colostomy not performed.
- •For lower extremity ulcers: Adequate arterial blood flow and perfusion near the site of the injury (the foot is warm to the touch and has palpable pulses), per Investigator judgement.
- •Confirmed pressure injury versus moisture-associated skin damage or friction injury.
- •Ability to maintain an intact occlusive dressing for 4-7 days with reinforcement without contamination of urine or stool.
- •Confirmed fecal (Colostomy) and/or urine incontinence (Foley) maintenance/management, if necessary.
- •Consent to off-loading (turns) from pressure sites a minimum of every 2 hours (if possible).
- •Consent to sharp debridement of necrotic tissue in the wound bed unless the wound has already undergone debridement within 5 days prior to the Treatment Visit.
- •For females of reproductive potential (defined as females ≤ 55 years of age): Negative pregnancy test required prior to surgical debridement per hospital procedures.
排除标准
- •Surgical treatment of pressure injury 30 days prior to the Treatment Visit and/or pressure injury in previously irradiated areas.
- •Inability to manage fecal and/or urine incontinence or patient refusal of its maintenance/management (as determined medically necessary). Patient may be rescreened and enrolled if urinary and/or fecal continence status or management change after failure to comply with requirement.
- •Allergy or hypersensitivity to materials in porcine-based study products (per subject report) or personal preference.
- •Currently treated for an active malignant disease.
- •Prior diagnosis of active malignant disease, and is less than 1 year disease-free.
- •History of malignancy within the wound.
- •Presence of any conditions that are contraindicated with NPWT.
- •Any condition associated with a wound healing abnormality (e.g.: connective tissue disorder or immune disorder).
- •Dermatologic comorbid disease (e.g., cutis laxa or collagen vascular disease).
- •Bleeding diathesis.
- •Patients with primary treatment ulcers from burns (from exposure to high heat) or venous leg ulcers. A patient may have concomitant non-pressure ulcers present in non-pressure ulcer treatment regions.
- •Received biological-based therapy in any pressure wound within 3 months of the Treatment Visit.
- •Severe or significant hypoalbuminemia (albumin <2.5 g/dL, and/or pre-albumin <5 mg/dL), or hypoproteinemia (protein <6 g/dL).
- •Moderate to severe anemia (Hgb <7 g/dL).
- •Severely uncontrolled diabetes mellitus (defined as HA1C >12%).
- •Subject report of concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study.
- •Subject report of previous participation in other interventional wound healing clinical investigation within 60 days prior to the Screening Visit.
- •The subject has any physical or psychiatric condition that in the Investigator's opinion would warrant exclusion from the study or prevent the subject from completing the study
结局指标
主要结局
Incidence of Complete Epithelialization
时间窗: 12 weeks
Number of participant wounds with complete epithelialization by 12 weeks. Complete wound closure (epithelialization) determination based on PI assessment.
次要结局
- Time to Complete Wound Epithelization(12 weeks)
- Rate of Wound Epithelization(12 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
3 期
Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ASevere Hemophilia ANCT06136507Jiangsu Gensciences lnc.76
进行中（未招募）
3 期
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AHemophilia ANCT06297655Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.60
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal InsulinDiabetesNCT06767748Gan & Lee Pharmaceuticals.620
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)DiabetesNCT06767735Gan & Lee Pharmaceuticals.580
进行中（未招募）
3 期
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial InsulinDiabetesNCT06767761Gan & Lee Pharmaceuticals.580